1448189-90-9

Basic information

• Product Name: (2S,4R)-4-hydroxy-N-{ [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide hydrochloride
• Synonyms: (2S,4R)-4-hydroxy-N-{ [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide hydrochloride
• CAS NO: 1448189-90-9
• Molecular Weight: 353.873
• Mol File: 1448189-90-9.mol
• Article Data: 20

Chemical Properties

• CAS DataBase Reference: (2S,4R)-4-hydroxy-N-{ [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-4-hydroxy-N-{ [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide hydrochloride(1448189-90-9)
• EPA Substance Registry System: (2S,4R)-4-hydroxy-N-{ [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide hydrochloride(1448189-90-9)

Safety Data

• Hazardous Substances Data: 1448189-90-9(Hazardous Substances Data)

Usage

Description

(2S,4R)-4-hydroxy-N- [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylpyrrolidine-2-carboxamide hydrochloride is a hydrochloride salt form of a pyrrolidine-2-carboxamide derivative with a unique chemical structure. It has a molecular formula of C17H21ClN4O2S and a molecular weight of 396.89 g/mol. (2S,4R)-4-hydroxy-N- [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylpyrrolidine-2-carboxamide hydrochloride features a 4-hydroxy-N-substituted pyrrolidine core structure with a 4-methyl-1,3-thiazol-5-yl substituted phenylmethyl group.

Uses

Used in Pharmaceutical Industry:
(2S,4R)-4-hydroxy-N- [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylpyrrolidine-2-carboxamide hydrochloride is used as a pharmaceutical compound for its potential therapeutic applications. Its unique chemical structure and properties may contribute to the development of new drugs and treatments.
Used in Research Settings:
In research, (2S,4R)-4-hydroxy-N- [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylpyrrolidine-2-carboxamide hydrochloride is used as a chemical probe to study biological processes and mechanisms. Its specific interactions with biological targets can provide insights into the development of novel therapeutic strategies and understanding of disease pathways.

Upstream product

• 68819-84-1 tert-butyl N-(4-bromobenzyl)carbamate 
• 2044838-29-9 1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methanamine hydrochloride 
• 489446-42-6 4-((tert-butoxycarbonylamino)methyl)phenylboronic acid 
• 623-00-7 4-bromobenzenecarbonitrile 
• 122957-57-7 4-(4-methyl-1,3-thiazol-5-yl)benzonitrile 
• 26177-44-6 4-bromobenzylamine hydrochloride 
• 1448189-30-7 1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methaneamine 
• 1448189-29-4 2-(trimethylsilyl)ethyl 4-(4-methylthiazol-5-yl)benzylcarbamate 
• 1448189-28-3 2-(trimethylsilyl)ethyl 4-bromobenzylcarbamate 
• 1448191-54-5 tert‐butyl (2S,4R)‐4‐hydroxy‐2‐({[4‐(4‐methyl‐1,3‐thiazol‐5‐yl)phenyl]methyl}carbamoyl)pyrrolidine‐1‐carboxylate 
• 1448189-89-6 tert-butyl (2S,4R)-2-[(4-bromophenyl)methylcarbamoyl]-4-hydroxypyrrolidine-1-carboxylate 
• 3959-07-7 4-Bromobenzylamine 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 

Downstream Products

• 1618678-46-8 (2S,4R)-1-((S)-2-(tert-butyl)-20-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-15-methyl-4-oxo-6,9,12-trioxa-3,15-diazaicosan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1618678-48-0 (2S,4R)-1-((S)-2-(tert-butyl)-19-((7R,8R,9S,13S,14S,17S)-3-hydroxy-17-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-4-oxo-6,9,12,15-tetraoxa-3-azanonadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1618678-49-1 (2S,4R)-1-((S)-2-(tert-butyl)-18-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-4-oxo-6,9,12-trioxa-3-azaoctadecan-1-oyl)-4-hydroxy-N-( 4-( 4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1618678-50-4 (2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butyl)-2-oxopiperazin-1-yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1618678-51-5 (2S,4R)-1-((S)-2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)butoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448189-71-6 (2S,4R)-1-[(2S)-2-amino-3-methylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide hydrochloride 
• 1448189-03-4 (2S,4R)-1-((S)-19-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta [a]phenanthren-7-yl)-2-isopropyl-4-oxo-6,9,12,15-tetraoxa-3-azanonadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448189-80-7 (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide hydrochloride 
• 1448189-04-5 (2S,4R)-1-((S)-2-(tert-butyl)-19-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-4-oxo-6,9,12,15-tetraoxa-3-azanonadecan-1-oyl)-4-hydroxy-N-( 4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448189-17-0 (2S,4R)-1-((S)-22-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-2-isopropyl-4-oxo-6,9,12,15,18-pentaoxa-3-azadocosan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448189-27-2 (2S,4R)-1-((S)-2-(tert-butyl)-21-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-16-methyl-4-oxo-7,10,13-trioxa-3,16-diazahenicosan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1618678-45-7 (2S,4R)-1-((S)-2-(tert-butyl)-14-(4-(5-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)pentyl)piperazin-1-yl)-4-oxo-6,9,12-trioxa-3-azatetradecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448189-98-7 tert‐butyl N‐[(2S)‐1‐[(2S,4R)‐4‐hydroxy‐2‐({[4‐(4‐methyl‐1,3‐thiazol‐5‐yl)phenyl]methyl}carbamoyl)pyrrolidin‐1‐yl]‐3,3‐dimethyl‐1‐oxobutan‐2‐yl]carbamate 
• 1448187-01-6 (2S,4R)-1-((S)-2-((S)-2-acetamido-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 

Relevant articles and documents

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS

The present invention relates to compounds comprising an interleukin-1 receptor-associated kinase 1 (IRAK1) protein binding moiety and a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety, and associated methods of use. The compounds are useful as modulators of targeted ubiquitination, especially with respect to IRAK1, which is degraded by the compounds according to the invention.

BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY

Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

SMARCA2-VHL DEGRADERS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.